首页> 外文期刊>International journal of clinical practice >Clinical value of CYFRA21-1, NSE, CA15-3, CA19-9 and CA125 assay in the elderly patients with pleural effusions.
【24h】

Clinical value of CYFRA21-1, NSE, CA15-3, CA19-9 and CA125 assay in the elderly patients with pleural effusions.

机译:CYFRA21-1,NSE,CA15-3,CA19-9和CA125检测在老年胸腔积液患者中的临床价值。

获取原文
获取原文并翻译 | 示例
       

摘要

The aim of this study was to evaluate the individual and combined diagnostic value of five tumour markers in the elderly patients with pleural effusions. Serum and pleural fluid levels of cytokeratin fragment 19 (CYFRA21-1), neuron-specific enolase (NSE), carbohydrate antigen 15-3 (CA15-3), carbohydrate antigen 19-9 (CA19-9) and carbohydrate antigen 125 (CA125) were assayed in 32 elderly patients with malignant pleural effusions resulting from advanced lung cancer and in 30 elderly patients with benign pleural effusions by ELISA. Serum levels of CYFRA21-1, NSE, CA15-3, CA19-9 and CA125 in patients with malignant pleural effusions were 12.84 +/- 6.48 mug/l, 22.07 +/- 11.25 mug/l, 65.74 +/- 30.26 kU/l, 56.32 +/- 25.6 kU/l and 71.86 +/- 31.45 kU/l, respectively, and were significantly higher than those in patients with benign pleural effusions (p < 0.01). Pleural fluid levels of CYFRA21-1, CA15-3, CA19-9 and CA125 except NSE in patients with malignant pleural effusions were 18.64 +/- 8.15 mug/l, 59.31 +/-27.35 kU/l, 48.24 +/- 21.56 kU/l and 62.16 +/- 27.79 kU/l, respectively, and were significantly higher than those in patients with benign pleural effusions (p < 0.01). The parallel combined testing of five tumour markers in serum increased the diagnostic sensitivity to 90.6%, and serial combined testing increased the diagnostic specificity to 93.3%. The sensitivity (%) and specificity (%) of these tumour markers in pleural fluid were as follows: CYFRA21-1, 84.4/90; CA15-3, 62.5/73.3; CA19-9, 37.5/66.7; CA125, 56.3/70; for differentiating malignant effusions from benign effusions. When CYFRA21-1 and CA15-3 combined, the sensitivity and specificity were increased (100% and 90% respectively). Serum and pleural fluid levels of the five tumour markers shows certain values in the diagnosis and differentiate diagnosis for malignant pleural effusions in the elderly patients from benign. The combined assay of five tumour markers in serum and the CYFRA21-1 combined with CA15-3 in pleural fluid were helpful and can increase the sensitivity and specificity in diagnosing malignant pleural effusions.
机译:这项研究的目的是评估老年胸膜积液患者中五种肿瘤标志物的单独和综合诊断价值。血清和胸水的细胞角蛋白片段19(CYFRA21-1),神经元特异性烯醇化酶(NSE),碳水化合物抗原15-3(CA15-3),碳水化合物抗原19-9(CA19-9)和碳水化合物抗原125(CA125) ELISA检测了32例老年晚期肺癌恶性胸腔积液老年患者和30例良性胸腔积液老年患者。恶性胸腔积液患者的血清CYFRA21-1,NSE,CA15-3,CA19-9和CA125的水平为12.84 +/- 6.48杯/升,22.07 +/- 11.25杯/升,65.74 +/- 30.26 kU /分别为l。,56.32 +/- 25.6 kU / l和71.86 +/- 31.45 kU / l,并​​显着高于良性胸腔积液患者(p <0.01)。恶性胸腔积液患者的除NSE以外的CYFRA21-1,CA15-3,CA19-9和CA125胸水水平为18.64 +/- 8.15杯/升,59.31 +/- 27.35 kU / l,48.24 +/- 21.56 kU / l和62.16 +/- 27.79 kU / l,分别显着高于良性胸腔积液患者(p <0.01)。血清中五种肿瘤标志物的平行联合检测将诊断灵敏度提高到90.6%,串行联合检测将诊断特异性提高到93.3%。这些肿瘤标志物在胸腔积液中的敏感性(%)和特异性(%)如下:CYFRA21-1,84.4 / 90; CA15-3,62.5 / 73.3; CA19-9,37.5 / 66.7; CA125,56.3 / 70;用于区分恶性积液和良性积液。当CYFRA21-1和CA15-3结合使用时,敏感性和特异性均增加(分别为100%和90%)。五种肿瘤标志物的血清和胸水水平在诊断良性恶性胸腔积液和鉴别诊断方面具有一定的价值。血清中五种肿瘤标志物和CYFRA21-1联合胸膜液中CA15-3的联合检测是有帮助的,可以提高诊断恶性胸腔积液的敏感性和特异性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号